# Herz Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/herz-life

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.hzlifetech.com/
- Latest round: Series B (Jan 26, 2026)
- Investors on record: 5

## About

Established in 2020 and based in Shenzhen, China, Shenzhen Herz Life Science Technology Co., Ltd., trading as Herz Life, is a developer that focuses on pet vaccines based on virus-like particle VLPs technology. In January 2026, Herz Life raised a series B funding from new investors Hainan Zhenmai Private Equity Fund Management, Real Power Capital, Tiantu Capital, and Shida Group.

Herz Life Science engages in the development of animal and human vaccines. Its main products include feline transabdominal vaccine and castration vaccine. The company generates revenue from providing its pet vaccine products.

The company generates revenue from providing its pet vaccine products.

## Funding rounds

- Series B, Jan 26, 2026 — Tiantu Capital, Real Power Capital, Hainan Zhenmai Private Equity Fund Management
- Series A, Sep 2, 2025 — NLVC
- Series A, Feb 1, 2025 — NLVC
- Seed, Sep 24, 2021 — Triwise Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Seed
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Tiantu Capital (https://capitalatlas.ai/funds/tiantu-capital) — Series B
- Real Power Capital (https://capitalatlas.ai/funds/real-power-capital) — Series B
- Hainan Zhenmai Private Equity Fund Management (https://capitalatlas.ai/funds/hainan-zhenmai-private-equity-fund-management) — Series B